News
ARDX
4.910
-2.00%
-0.100
Weekly Report: what happened at ARDX last week (0113-0117)?
Weekly Report · 2d ago
HC Wainwright & Co. Reiterates Neutral on Ardelyx, Maintains $5.5 Price Target
Benzinga · 6d ago
Ardelyx’s Mixed Financial Outlook: Hold Rating Amid IBSRELA Growth and XPHOZAH Challenges
TipRanks · 6d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 01/15 16:15
Ardelyx’s Strategic Outlook and Financial Strength Indicate Strong Buy Potential
TipRanks · 01/15 07:10
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
NASDAQ · 01/14 14:07
TD Cowen Remains a Buy on Ardelyx (ARDX)
TipRanks · 01/14 12:56
Ardelyx provides update on commercial progress; shares up 8%
Seeking Alpha · 01/13 17:32
Ardelyx Announces 2024 U.S. Sales Of $319M, Projects IBSRELA To Surpass $1B, XPHOZAH At $750M; Ends Year With $250M In Cash And Investments
Benzinga · 01/13 13:57
Ardelyx reports preliminary Q4 IBSRELA revenue $54M
TipRanks · 01/13 13:51
*Ardelyx Backs 2024 Peak U.S. Net IBSRELA Sales Rev of Greater Than $1B >ARDX
Dow Jones · 01/13 13:18
ARDELYX INC - 2024 U.S. NET PRODUCT SALES REVENUE APPROXIMATELY $319 MILLION
Reuters · 01/13 13:03
Weekly Report: what happened at ARDX last week (0106-0110)?
Weekly Report · 01/13 10:23
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
Barchart · 01/13 07:03
Weekly Report: what happened at ARDX last week (1230-0103)?
Weekly Report · 01/06 10:28
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock
Benzinga · 01/02 20:00
Ardelyx Is Maintained at Buy by Jefferies
Dow Jones · 01/02 16:31
Ardelyx Price Target Cut to $8.00/Share From $11.00 by Jefferies
Dow Jones · 01/02 16:31
Jefferies Maintains Buy on Ardelyx, Lowers Price Target to $8
Benzinga · 01/02 16:23
U.S. RESEARCH ROUNDUP-Biogen, Crown Castle, Eastgroup Properties
Reuters · 01/02 14:57
More
Webull provides a variety of real-time ARDX stock news. You can receive the latest news about Ardelyx through multiple platforms. This information may help you make smarter investment decisions.
About ARDX
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.